North America Epilepsy Drugs Market Forecast to 2030

According to the Research Team’ research, the North America epilepsy drugs market was valued at US$ 2,575.83 million in 2022 and is expected to reach US$ 3,609.34 million by 2030, registering a CAGR of 4.3% from 2022 to 2030. Increasing product approvals and growing prevalence of epilepsy are among the critical factors attributed to the North America epilepsy drugs market expansion.

In recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs.

Drug approvals and the diversity of new molecular entities (NMEs) upon which new drugs are based have been consistently growing over time. A notable growth in the number of drug approvals annually was also observed in the recent past. Thus, the acceptance of new drugs is rising and resulting in increasing approvals for the products. A few recent approvals are mentioned below – In December 2022, Zydus Lifesciences received approval from the US health regulator to market Topiramate extended-release capsules, used to control and prevent seizures in people with epilepsy, in the American market. The US FDA approved multiple strengths of the product to market. Topiramate is indicated to prevent and control seizures in individuals with epilepsy. In March 2022, Marinus Pharmaceuticals, Inc. announced that the US FDA approved ZTALMY (ganaxolone) oral suspension to treat seizures associated with cyclin-dependent kinase-like five deficiency disorder (CDD), a rare type of genetic epilepsy, in patients aged 2 years and above. Thus, the increasing number of regulatory approvals is becoming a trend in the North America epilepsy drug market.

On the contrary, recall of therapeutic products hampers the growth North America epilepsy drugs market.

Based on treatment, the North America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held 42.6% share of the North America epilepsy drugs market in 2022, amassing US$ 1,097.23 million. It is projected to garner US$ 1,591.51 million by 2030 to expand at 4.8% CAGR during 2022-2030.

Based distribution channel, the North America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held 51.0% share of the North America epilepsy drugs market in 2022, amassing US$ 1,312.44 million. It is projected to garner US$ 1,778.97 million by 2030 to expand at 3.9% CAGR during 2022-2030.

Based on country, the North America epilepsy drugs market is categorized into the US, Canada, and Mexico. The US held 75.4% share of North America epilepsy drugs market in 2022, amassing US$ 1,942.38 million. It is projected to garner US$ 2,749.86 million by 2030 to expand at 4.4% CAGR during 2022-2030.

Key players operating in the North America epilepsy drugs market are Abbott Laboratories, Alkem Laboratories Ltd, Catalyst Pharmaceuticals Inc, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd, and UCB SA, among others.

In October 2023; Novartis completed the Sandoz’s spin-off through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts. Each holder received one Sandoz share for every five Novartis shares held at the close of business on October 3, 2023. The separation of Sandoz has led Novartis to complete its transformation, allowing it to focus as a medicines company.

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Epilepsy Drugs Market Landscape
4.1 Overview
5. North America Epilepsy Drugs Market – Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market – North America Market Analysis
6.1 Overview
6.2 North America Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
7. North America Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 North America Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 North America Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Epilepsy Drugs Market – Revenue and Forecast to 2030 – Country Analysis
9.1 North America Epilepsy Drugs Market
9.1.1.1 US: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 US: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 US: North America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.1.4 US: North America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Canada: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 Canada: North America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.2.4 Canada: North America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 Mexico: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 Mexico: North America Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.3.4 Mexico: North America Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Epilepsy Drugs Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

Table 1. North America Epilepsy Drugs Market Segmentation
Table 2. US: North America Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 4. Canada: North America Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 5. Canada: North America Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 6. Mexico: North America Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 7. Mexico: North America Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 9. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 10. Glossary of Terms, North America Epilepsy Drugs Market

Figure 1. North America Epilepsy Drugs Market Segmentation, By Country
Figure 2. North America Epilepsy Drugs Market: Key Industry Dynamics
Figure 3. North America Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 6. First Generation Anti-epileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Second Generation Anti-epileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Third Generation Anti-epileptics: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 10. Hospital Pharmacy: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Retail Pharmacy Stores: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. North America Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 14. North America Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 15. US: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Canada: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Mexico: North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Growth Strategies in the Epilepsy Drugs Market